Else Nutrition Holdings (TSXV:BABY) (OTCPK:BABYF) continues to rocket up the markets this week. The food and nutrition company currently targeting infant, toddler, and children markets shows no signs of slowing down, so Rich is bringing you another interview with the company’s management.
After interviewing Else’s Director of Digital Marketing, Barak Orenstein, Rich wanted to go even higher up the ladder. Today, he’s talking with Else Nutrition’s CEO Hamutal Yitzhak, who is also a co-founder of the company. Before starting BABY, Yitzhak was the head of Infant Nutrition at Abbott Labs Israel.
Rich and Yitzhak discuss the pain point that her company is addressing in the industry.
Else Nutrition Addresses an Important Need
“[Infant formula] is a market with only two alternatives, and both of them are not good,” Yitzhak explains. “We’re the third one, and we’re bringing a superior product.”
The alternatives she’s referring to are cow-based protein infant formula and soy-based formula. Both dairy and soy are allergens, and, in fact, cow’s milk is the number one allergen for children aged five or younger.
Else Nutrition’s formula is a 100% plant-based formula. It’s derived entirely from almonds and buckwheat and contains zero GMOs, pesticides, hormones, antibiotics, gluten, and phytoestrogens.
“We’re a non-dairy, non-soy, 100% plant-based infant formula. We’re the only one that exists, so there’s no other alternative,” says Yitzhak.
She also explains that the product was created not only to fill the need for a non-diary, non-soy formula but also to provide parents a healthier option for their children. Approximately 1 in 12 families are raising their children vegan, which means there are millions of children who can benefit almost exclusively from Else’s formula.
Else’s Growth Potential
“Our first target market is the North American market,” says Yitzhak. She adds that Else Nutrition has been inundated with requests from interested parents who want to know when and where they can buy its product.
But BABY’s growth isn’t just limited to North America. The company is registered in 66 countries, with 18 patents granted and 45 patents pending.
Another factor that is likely to catapult the company to success is its management team. Yitzhak says that every member of the team brings considerable experience in the fast-moving consumer goods industry. Additionally, several members have an extensive background in childhood health and nutrition fields.
BABY’s Booming Stock Price
Rich first brought Else Nutrition to the attention of his community on October 18 when he profiled the exciting company. Since then, BABY stock has grown faster and stronger than an actual baby drinking Else Nutrition’s 100% plant-based infant formula.
The company has risen an incredible 61.3% since mid-October, almost entirely on excitement over BABY’s product portfolio and potential to control an incredibly lucrative market. The company’s share price is currently $0.50 on the TSX Venture Exchange.
The company’s real potential will likely come next spring, as it introduces its formulas to the market. Make sure to keep watching this company as it grows, and keep watching RichTV Live for more stock market news and corporate profiles.
Let us know what you think about Else Nutrition in the comments below.
Featured image: Else Nutrition